Safety and Efficacy of AL-53817 Nasal Spray Solution
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A)
and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis
(Stage B).